|
Ault KA, Future II study group. Effect of prophylactic human
papillomavirus L1 virus-like-particle vaccine on risk of cervical
intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:
a combined analysis of four randomised clinical trials. Lancet. 2007 Jun
2;369(9576):1861–1868
Bast RC, Zalutsky MR, Kreitman RJ, Frankel AE. Monoclonal
serotherapy. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE,
Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine 7.
Hamilton, Ontario: BC Decker, Inc.;2006:770–785.
Chesney J, Rasku M, Clem A, Miller D. Denileukin diftitox
depletes T regulatory cells and causes regression of melanoma
metastases in humans [abstract]. Eur
J Cancer Suppl. 2006;4:12:84.
Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of
immunity to the HER-2/neu oncogenic protein in patients with breast and
ovarian cancer using a peptide-based vaccine. Clin Cancer Res.
1999;5:1289–1297.
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression
and autoimmunity in patients after clonal repopulation with antitumor
lymphocytes. Science.
2002;298:850–854.
Ekmekcioglu S, Grimm EA, Kurzrock R. Cytokines and
hematopoietic growth factors. In: Kufe DW, Bast RC, Hait WN, Hong WK,
Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine 7.
Hamilton, Ontario: BC Decker, Inc.;2006:744–769.
Hodge JW, Schlom J, Abrams SI. Vaccines and immunostimulants.
In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR,
Holland JF, Frei E, eds. Cancer
Medicine 7. Hamilton, Ontario: BC Decker,
Inc.;2006:786–801.
Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific
immunotherapy with polyvalent melanoma cell vaccine for patients with
in-transit melanoma metastases. Cancer.
1999;85:2160–2169.
Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the
anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant
hairy-cell leukemia. N
Engl J Med. 2001;345:241–247.
Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression
in patients after transfer of genetically engineered lymphocytes.
Science. 2006;314:126–129.
Morse MA, Clay TM, Lyerly HK. Handbook of Cancer Vaccines.
Totowa NJ: Humana Press, 2004.
Nemunaitis J, Sterman D, Jablons D, et al.
Granulocyte-macrophage colony-stimulating factor gene-modified
autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer
Inst. 2004;96:326–331.
Restifo NP, Robbins PF, Rosenberg SA. Principles of
immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer:
Principles and Practice of Oncology. 8th ed. Philadelphia, Pa:
Lippincott Williams & Wilkins; 2008:351–368.
Robinson MK, Borghaei H, Adams GP, Weiner LM. Monoclonal
antibodies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer:
Principles and Practice of Oncology. 8th ed. Philadelphia, Pa:
Lippincott Williams & Wilkins; 2008: 537–548.
Salgaller ML. Immune adjuvants. In: Rosenberg SA, ed.
Principles and Practice of the Biologic Therapy of Cancer. 3rd ed.
Philadelphia, Pa: Lippincott Williams & Wilkins;
2000:584–601.
Small EJ, Schellhammer PF, Higano CS, et al.
Placebo-controlled phase III trial of immunologic therapy with
sipuleucel-T (APC8015) in patients with metastatic, asymptomatic
hormone refractory prostate cancer. J Clin Oncol.
2006;24:3089–3094.
Go back
to Immunotherapy.
Last Medical Review: 08/25/2009
Last Revised: 08/25/2009
|
